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ABSTRAK 
Tajuk: Prevalen “latent tuberculosis infection” dan faktor-faktor yang berkaitan 
tentangnya di kalangan pesakit diabetik di Hospital Universiti Sains Malaysia. 
 
XII 
 
Pengenalan: Hubungkait di antara penyakit tuberkulosis dan penyakit diabetik adalah 
lebih penting dan menonjol di negara sedang membangun seperti Malaysia, di mana 
penyakit tuberkulosis adalah endemik dan beban penyakit diabetik semakin meningkat. 
 
Objektif: Untuk menentukan prevalen “latent tuberculosis infection” di kalangan pesakit 
diabetik di Hospital Universiti Sains Malaysia faktor-faktor yang berkaitan tentangnya. 
 
Metodologi: Kajian berbentuk “cross sectional” (dijalankan di antara Oktober  2013 
hingga Januari 2015). “Mantoux test”dilakukan terhadap pesakit yang berkelayakan dan 
memberi persetujuan untuk mengambil bahagian di dalam kajian ini, dan bacaan ujian 
dilakukan selepas 72 jam. Peserta yang mempunyai bacaan Mantoux sebanyak 10mm 
ataupun lebih bersama dengan X ray dada yang normal didiagnosa sebagai LTBI. 
 
Keputusan: Kadar respons kajian ini adalah 93.7%, di mana 319 peserta diuji dengan 
“tuberculin skin test”. Prevalen “latent tuberculosis infection” di kalangan pesakit 
diabetik adalah 11.4%. Tahap pendidikan didapati mempunyai hubungkait yang 
signifikan dengan LTBI; sementara faktor-faktor berkaitan lain yang diuji (umur, 
jantina, status merokok, ko-morbid lain, tempoh penyakit diabetik, keputusan HbA1c 
dan rawatan insulin) tidak menunjukkan hubungkait yang signifikan dengan “latent 
tuberculosis infection” di kalangan pesakit diabetik. 
 
XIII 
 
Konklusi: Prevalen “latent tuberculosis infection” di kalangan pesakit diabetik di 
Malaysia adalah rendah secara relatif memandangkan negara kita mempunyai beban 
penyakit tuberkulosis yang intermediate. Walau bagaimana pun, hasil kajian preliminari 
ini memberi “baseline data” bagi reservoir “latent tuberculosis infection” di kalangan 
pesakit diabetik di populasi kita, yang amat penting bagi isu “tuberculosis 
chemoprophylaxis” untuk golongan ini. 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT 
Title: Prevalence of latent tuberculosis infection and its associated factors among 
patients with diabetes in Hospital Universiti Sains Malaysia. 
XIV 
 
 
Introduction:  The important association between tuberculosis and diabetes mellitus is 
even more prominent in developing countries, including Malaysia, where tuberculosis is 
endemic and the burden of diabetes mellitus is fast increasing.  
 
Objectives: To determine the prevalence of latent tuberculosis infection among patients 
with diabetes and factors associated with it. 
 
Methodology: A cross sectional study was conducted from October 2013 to January 
2015. Mantoux test was performed on the patients whom are eligible and gave consent 
to participate in the study and reading was carried out at 72 hours. Respondents with 
mantoux reading of 10mm or more with a normal chest radiograph were diagnosed with 
LTBI. 
 
Results: The response rate for this study was 93.7% with 319 respondents tested with 
tuberculin skin test for latent tuberculosis infection. The prevalence of latent 
tuberculosis infection among diabetic patients was 11.4%. Education level was 
significant associated with LTBI; while other factors studied (age, gender, duration of 
diabetes, HbA1c result, smoking status, presence of any co-morbities and on insulin 
treatment) showed no significant association with latent tuberculosis infection in 
diabetic patients. 
 
XV 
 
Conclusion: The prevalence of latent tuberculosis infection in Malaysia was relatively 
low for an intermediate tuberculosis burden country. However this preliminary evidence 
provides a baseline data on the reservoir of latent tuberculosis infection among diabetic 
group in our setting, which is especially important in the issue of tuberculosis 
chemoprophylaxis for latent tuberculosis infection among patients with diabetes. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Tuberculosis epidemiology and burden globally and in Malaysia 
 
Tuberculosis (TB) is ranked second only to HIV/AIDS as the greatest killer worldwide 
due to a single infectious agent. In year 2013, 9 million people fell ill with tuberculosis 
and 1.5 million died from the disease. The majority of tuberculosis deaths occur in the 
developing countries. More than half (56%) of the new tuberculosis cases  were from 
South-East Asia and Western Pacific Regions; followed by  a further one quarter from 
African Region, and 24% and 11% from India and China.(1)   
 
It is reported that some countries are showing a major drop in tuberculosis cases; while 
in others the numbers are dropping very slowly.(2) For example, Brazil and China has a 
sustained decline in tuberculosis cases over past 20 years; and in Cambodia tuberculosis 
prevalence fell by almost 50%. In 2002, tuberculosis was classified as the eighth leading 
cause of death, and it is projected to fall to the twenty third leading cause of death in 
year 2030.(3)  The 2015 Millennium Development Goal (MDG) of halting and 
reversing TB incidence has been achieved globally, in all six WHO regions and in most 
of the 22 high TB burden countries, with the tuberculosis incidence falling at an average 
rate of 1.5% per year between year 2000 and 2013.  Meanwhile, worldwide tuberculosis 
mortality rate has dropped 45% between 1990 and 2013 and tuberculosis prevalence 
rate fell by 41%.  Much need to be done to reach the Stop TB Partnership targets of a 
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50% reduction by 2015. Among the three 2015 targets for reduction in TB disease 
burden ( incidence, prevalence, mortality), 2 out of 6 WHO regions (the Region of the 
Americas and the Western Pacific Region) have achieved all three of them.   South East 
Asia Region seems to be on track to achieve the three targets; where in the African, 
Eastern Mediterranean and European Regions those targets are falling but not in a pace 
fast enough to meet targets.(1)  And it is projected that TB will cause 21.8 million 
disability life years loss in year 2015, again ranking second only to HIV in this 
category.(4)  
 
Malaysia is a country with an intermediate burden of tuberculosis; is reported to have a 
TB prevalence of 131/ 100,000 and incidence of 99/ l00, 000 populations.(5)  There is a 
rise in tuberculosis incidence between year2011 and 2012. A concurrent rise in rate of 
relapse was also reported, thus rendering tuberculosis still a public health problem in 
Malaysia.(6) In year 2013, the tuberculosis mortality rate is 5.8/ 100,000 population 
(excludes HIV + TB); and 1.5/ 100,000 population (HIV+ TB only). The increase in 
non-communicable diseases and demographic shift towards population senescence has 
attributed to the resurgence of tuberculosis. Tuberculosis in Malaysia is also 
compounded by the HIV pandemic, complacency, neglect towards the disease, and 
international movement. 
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1.2 Diabetes mellitus prevalence globally and in Malaysia 
 
 Diabetes mellitus prevalence is soaring globally, fuelled by obesity, changing patterns 
of diet and physical activity, and aging populations. The number of people with 
diabetes, which was 171 million in year 2000, is expected to grow to 366-440 million in 
year 2030. Three quarters of these patients live in low-income countries.(7-9)  In 
Malaysia the prevalence of diabetes continue to rise; the fourth National Health and 
Morbidity Survey 2011 showed that the prevalence of type 2 DM for adults age 18 
years old and above is 15.2%. In fact, Malaysia has already reached its projected of 
prevalence of diabetes for the year 2025.(10) 
 
1.3 Double burden of tuberculosis and diabetes mellitus 
 
Although HIV infection is considered the most potent risk factor for TB, many studies 
showed that the high prevalence of DM worldwide and its effect on TB burden is 
greater than HIV infection.(11)  Worldwide 70% of diabetics live in TB endemic 
countries. Eight of the ten countries with the highest incidence of DM are also classified 
as high burden countries for TB.(12)  This link of DM and TB is more prominent in 
developing and low-income countries, where the provision of tuberculosis care are 
complicated as tuberculosis , poverty, poor access to health services are all closely 
linked.(13)  And at the same time treatment of diabetes poses a large financial burden in 
these countries with limited resources. In the setting of the increasing overlap of 
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populations at risk for both diseases, TB and DM combined represent a health threat 
globally. 
 
 
1.4 Justification of study 
 
The first report on the association between DM and TB was documented by Avicenna 
(980-1027 AD) over a thousand years ago.  A meta-analysis shows that DM increases 
the risk of TB, regardless of different study designs, background TB incidence or 
geographic region.(14) The cohort studies reveal that diabetic patients have 
approximately 3-fold risk of developing active TB compared to non-diabetics.(14)  
Diabetic patients with concurrent TB infection have poorer treatment outcomes.(15)  
Studies available on DM and TB generally focus on active TB disease. A review of 232 
patients diagnosed with tuberculosis at a medical facility in Malaysia, 17.7% of the 
patients have underlying diabetes mellitus – the percentage for this risk factor was the 
highest in contrast to all other associated risk factors.(16)  Active case findings among 
diabetics are among the interventions carried out to control TB. 
 
However the risk of developing active tuberculosis is a two-step process, the initial 
exposure and infection by Mycobacterium tuberculosis, followed by subsequent 
progression to the disease. And reactivation of the disease is largely under the influence 
of immune sufficiency, thus the reactivation risk to TB from latent TB state is higher in 
immunocompromised individuals, such as in the diabetic group. With the rise of 
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diabetic prevalence and an intermediate tuberculosis disease burden in the country, 
diabetic patients in Malaysia should be considered a high risk population prone to 
tuberculosis reactivation.  Studies on latent TB infection among DM patient are scarce.  
 
 A huge gap in global TB control today is the eradication of TB reservoir in human 
population.  A two pronged approach involving the coupling of primary with secondary 
control is recommended as treatment efficacy of both LTBI and the active disease work 
in synergy.(17)  Currently, screening of LTBI was focused on healthcare workers 
(HCWs), contacts of tuberculosis patients and drug abusers. But the high rising 
prevalence of DM globally and in Malaysia deems an early intervention, i.e. screening 
for latent TB in this at risk population a feasible proposition in the Malaysian context, in 
the track to control TB transmission. 
 
 
 
 
 
 
 
 
 
7 
 
 
 
 
 
Chapter 2 
_______________________  
Literature Review 
 
 
 
 
 
8 
 
CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Latent Tuberculosis Infection 
 
Latent tuberculosis infection (LTBI) is defined as a state of persistent immune response 
to stimulation by Mycobacterium tuberculosis antigens without evidence of clinically 
manifested active TB. It is estimated that one third of the world’s population is infected 
with latent TB.(18)  Infected persons are asymptomatic and not infectious, but are at 
risk of progression to active TB disease.(19)  And if untreated, the estimated risk of 
developing symptomatic tuberculosis disease is 5-10% over a lifetime, with about half 
of that risk occurring during the first year or two after infection.  
 
The risk of developing TB disease following infection depends on several factors, the 
most important one being the immunological status of the host, and thus the risk is 
increased in persons with HIV infection, diabetes, and other chronic conditions; those 
using immunosuppressant medications; and those with apical fibronodular changes on 
chest radiography, and children younger than four years.(19-21)  
 
However, in the country, the prevalence of latent tuberculosis infection (LTBI) was 
studied in only few specific groups, including among healthcare workers, prisoners and 
tuberculosis contacts. A cross sectional study was conducted at four randomly selected 
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hospitals in the Klang Valley from December 2008 to May 2009  and the overall 
prevalence of latent tuberculosis infection among health care workers was 10.6% (CI: 
8.6%; 12.6%).(22) Another study carried out among Healthcare workers in the 
University of Malaya Medical Centre, Kuala Lumpur  was done  to determine the 
occupational risk of Mycobacterium tuberculosis infection among healthcare workers 
and found that  52.1%  of  the healthcare workers tested had indurations of 10 mm or 
greater.(23)  Among prisoners with and without HIV infection in a prison in Kelantan, a 
cross sectional survey showed that LTBI prevalence was 87.6%, with significantly 
lower TST reactivity among HIV infected than non HIV infected prisoners (83.6% 
vs.91.5%).(24) A cross-sectional convenience survey was conducted to assess the 
prevalence and correlates of LTBI among attendees at a recently created voluntary drug 
treatment center, and showed positive TST prevalence of 86.7%.(25) 
 
A cross sectional study was carried out to compare the prevalence of M. tuberculosis 
infection among the household contacts of HIV-positive and HIV-negative pulmonary 
tuberculosis patients. 30% of the contacts of HIV-positive PTB had a positive tuberculin 
compared with 52.8% of the contacts of HIV-negative patients.(26) Targeted testing is 
an essential TB prevention and control strategies that identify, evaluate, and treat 
persons who are at high risk for latent TB infection or at high risk for developing TB 
disease once infected with M. tuberculosis. With the alarming increase in the trend of 
DM in the country, which falls in the high risk groups to progress from latent TB to 
active TB, the feasibility of screening of this group of patients becomes even more 
crucial.  
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2.2 Latent Tuberculosis Infection in patients with diabetes 
 
Patients with diabetes have increased susceptibility M. tuberculosis infection through 
multiple mechanisms, which include those directly related to hyperglycaemia and 
cellular insulinopenia, as well as indirect effects on macrophage and lymphocyte 
function which lead to diminished ability to contain the organism. 
 
The most important effector cells for containment of tuberculosis are phagocytes 
(alveolar macrophages and their precursor monocytes) and lymphocytes. Diabetes is 
known to affect chemotaxis, phagocytosis, activation, and antigen presentation by 
phagocytes in response to M. tuberculosis. In diabetic patients, chemotaxis of 
monocytes is impaired, and this defect does not improve with insulin.(27) In a study of 
patients with tuberculosis, alveolar macrophages were less activated and had decreased 
hydrogen peroxide production in those with diabetes.(28)  
 
Diabetes might adversely affect T-cell production of interferon γ, and T-cell growth, 
function, and proliferation. Interferon γ potentiates the nitric-oxide-dependent 
intracellular killing activity of macrophages. In experiments involving mice with 
induced diabetes that were challenged with M. tuberculosis, concentrations of interferon 
γ were diminished, and production of inducible nitric-oxide synthase by macrophages 
was low;(29) and the bacterial burden was also higher than in control mice. (30) 
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The available studies point to depressed immunological function in diabetes mellitus 
that might predispose a patient to infections for which cell-mediated immunity plays an 
important role, such as tuberculosis. Decreased phagocyte and T-cell function are likely 
contributors.  
 
Studies on latent TB infection among DM patient are scarce. One transversal 
observational study in Spain was carried out to determine the frequency of Tuberculin 
positives in diabetic population in a general medicine clinic. It reported 69 (42.2%) of 
163 diabetic patients to have a positive tuberculin skin test. There was a statistically 
significant relationship (p<0.001) between positive Mantoux test and the age of patients. 
(31) 
 
 Another observational cross survey to study the prevalence of tuberculosis infection in 
235 diabetics, and also to study the relationship of years of the illness and patient’s age 
with the infection. Mantoux test measured at 72 hours  yield  a prevalence of  
tuberculosis infection of 11.53%, without significant statistical association with the 
years of evolution of diabetes (p=0.097). The average years of evolution of diabetes, 
8.15 was associated significantly with the PPD (in mm) (p=0.00031) with a low 
association power (r=0.314).  The average age, 62.6 years was significantly associated 
with PPD (mm) (p=0.0022), with a low association power (r=0.191).(32)  
 
Leow et.al from Tan Tock Seng Hospital conducted a cross-sectional study to elucidate 
latent TB infection prevalence and longitudinal follow up to ascertain latent TB 
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infection to active TB progression rate in 220 diabetic patients. Study results showed 
prevalence of latent TB infection of 28.2% by reactive T-Spot. None progressed to 
active TB from year 2007-2013. Furthermore, any co-morbidity was positively 
associated (p=0.016) while metformin was negatively associated (p=0.008) with latent 
TB infection.(33)  
 
Results of one study showed the reaction to purified protein derivate (PPD) is 
significantly correlated to the degree of hyperglycemia.(34) Another cross sectional 
study showed that poor glycaemic control (hazard ratio 1.39, 95%CI 1.18–1.63 per unit 
increase in HbA1c) was associated with active TB disease which has Mantoux test ≥10 
mm.(35) An Australian cohort study revealed that the risk for TB is higher among 
people with diabetes who are using insulin; the crude RR of TB of 1.78 (95% CI 1.17 to 
2.73) in people with DM and 2.16 (95% CI 1.19 to 3.93) in people with DM using 
insulin.(36)  
 
Chan-Yeung et al carried out a cross sectional study to determine the prevalence of 
tuberculous infection and the predictors of positive tuberculin reactivity among old aged 
home residents in Hong Kong.(37) Of 3682 residents (mean age 82 years) who 
underwent a TST, 46.3% had a positive reaction. Factors associated with a significantly 
higher risk of a positive TST included being male, an ex- or current smoker and having 
a past history of tuberculosis.(37) 
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2.3 Methods of assessing latent TB infection 
 
Traditionally, LTBI is diagnosed based on the following criteria:  
1. No symptoms to suggest active disease 
2. Normal CXR/static CXR findings. 
3. Smear/culture negative on sputum or bronchoalveolar lavage for Mycobacterium 
tuberculosis (if collected) 
4. Positive TST (Mantoux test). Interferon-gamma release assays (IGRAs) may be 
used as an alternative test in all situations for adults. 
 
There are two testing methods available for the detection of Mycobacterium 
tuberculosis infection, namely Mantoux tuberculin skin test (TST) and Interferon-
gamma release assays (IGRAs). The TST induces a delayed hypersensitivity reaction 
that is detectable 2-12 weeks after infection with M. tuberculosis. Positive TST is 
interpreted on a graded-system based on positive predictive values (PPVs) which are 
largely dependent on the risk of acquiring the disease and risk of latent TB 
reactivation.(38) There is no good evidence to support the various cut-off measurements 
of TST in diagnosing LTBI for individuals living in high prevalence countries with 
moderate/high risk of developing TB reactivation. Thus, the Development Group of 
CPG TB Malaysia (3rd edition) suggests that a TST of ≥10 mm should be considered as 
a positive test for LTBI for most individuals investigated in this country except for 
categories listed in the Table  2.1 below:(39) 
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Table 2.1: Positive TST for LTBI 
Positive TST Reaction 
(Measurement) 
Type of Individual 
≥5 mm  HIV-infected persons 
Organ transplant recipients 
Persons who are immunosuppressed for other reasons 
(such as those taking the equivalent of >15 mg/day 
prednisolone for ≥1 month or taking TNF-α antagonists) 
≥15 mm Individuals from countries with low incidence of TB 
≥10 mm All other high risk individuals 
  
However, the interpretation of the result is compounded by the fact that the reagent 
(tuberculin) used in the test cross-reacts with BCG and NTM. This gives rise to false 
positive results in some individuals. 
 
IGRAs are the newer tests for LTBI screening. These in vitro blood tests evaluate T-
lymphocyte responses to M. tuberculosis–specific antigens, such as early secretory 
antigenic target-6 and culture filtrate protein-10. At the moment, there are two 
commercial tests available, i.e. the T-SPOT.TB (Oxford, Immunotec) and the QFT-GIT 
Test (Cellestis). They employ certain antigens like the ESAT-6 and CFP-10 (for T-
SPOT and QFT-GIT), as well as TB7.7 (only for QFT-GIT) to stimulate the production 
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of Interferon-γ from the T-cell lymphocytes. These antigens do not cross-react with the 
BCG and most NTM.(38)  Advantages of IGRAs include single visit, does not cause 
booster phenomenon, and the tests are not affected by healthcare worker bias, results 
available within 24 hours, unaffected by BCG and most environmental mycobacteria. 
Limitations include that of blood sample must be processed within 8-30 hours after 
collection, limited data on use in children younger than 5 years, persons recently  
exposed to TB, immunocompromised persons, and those who will be tested repeatedly. 
A meta-analysis comparing IGRAs and TST in low TB prevalence countries showed 
that IGRAs have higher specificity and better PPV and NPV than TST in adult 
population.(40) 
 
However, in low-income and middle-income countries, WHO recommends that IGRA 
should not replace TST to test for LTBI.(41)  For these countries with high incidence of 
TB, (usually from low and middle income countries), the expert group commissioned 
by WHO  concluded that the quality of evidence on the use of IGRAs in LTBI 
screening for healthcare workers, contacts and outbreak investigations in low and 
middle income countries is very low. The data could not be pooled due to heterogeneity 
in study designs and outcomes. Majority of studies showed comparable LTBI 
prevalence by TST or IGRA in contacts; four studies reported a statistically significant 
difference between positivity rates estimated by TST, T-SPOT or QFT. Both IGRAs 
and the TST seemed to show positive associations but the strength of the association 
(after adjustment) varied across studies, irrespective of BCG vaccination. These results 
indicated that concordance between TST and IGRAs ranged widely.(40) 
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The Development Group suggests that the situations where IGRAs may be used are as 
follow: (39) 
i. alternative to TST for 
• patients who are not expected to/could not come back for Mantoux test reading  
• patients who had recent BCG vaccination or past NTM infection 
ii. Where a 2-step test is considered (TST followed by IGRA) 
• close-contacts whose TST is in the range of 5 - 9 mm 
• patients who are offered LTBI treatment but are not convinced that they have 
LTBI 
• individuals who require annual screening of LTBI such as healthcare providers 
working in high risk areas 
 
CXR helps to differentiate between LTBI and pulmonary TB in individuals with 
positive tests for TB infection. A CXR should be ordered as part of a medical evaluation 
for individuals who have a positive TST or IGRA result.(42) 
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CHAPTER 3 
OBJECTIVES 
 
3.1 General objective  
To determine the prevalence of LTBI and its associated factors among patients with 
diabetes in HUSM. 
 
3.2 Specific objectives 
1. To determine the prevalence of LTBI among patients with diabetes. 
2. To determine associated factors of LTBI among patients with diabetes.  
 
3.3 Research hypothesis 
Patient’s age, male sex, presence of any co morbidity, duration of diabetes, HbA1c 
result, smoking, on insulin treatment are significant associated factors for LTBI among 
patients with diabetes in HUSM. 
 
3.4 Operational definitions 
LTBI is diagnosed based on the following criteria: 
1. No symptoms to suggestive of TB disease 
2. Positive TST (Mantoux test) with a reading of 10mm or more 
3. Normal chest radiograph 
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Presence of any co morbidity includes hypertension, dyslipidemia, bronchial asthma, 
chronic obstructive pulmonary disease, ischemic heart disease and stroke. 
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CHAPTER 4 
METHODOLOGY 
 
4.1 Study design 
Study design: cross sectional study 
 
4.2 Population and sample  
4.2.1 Reference population 
Diabetes patients in Kota Bharu, Kelantan  
 
4.2.2 Source population 
Diabetes patient attending outpatient clinic HUSM from October 2013 to January 2015. 
 
4.2.3 Inclusion criteria  
Patient with diabetes mellitus 
 
4.2.4 Exclusion criteria  
1) Diagnosed TB (current/ previous) 
2) Patients with symptoms suggestive of TB 
3) HIV-infected persons 
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4) Organ transplant recipients 
5) Persons who are immunosuppressed for other reasons (such as those taking the   
equivalent of > 15mg/day prednisolone for ≥ 1 month or taking TNF-α  antagonists) 
6) Non Malaysian  
 
 
4.2.5 Sampling method 
Systematic random sampling in the ratio 1:1 based on attendance list at outpatient 
clinic, HUSM. 
 
 
4.2.6 Sample size calculation 
Sample size for objective 1 i.e. to determine the prevalence of LTBI among patients 
with diabetes was done using single proportion formula. 
n = ( z / Δ )² p ( 1 – p ) 
n = minimum required sample size 
z = value of standard normal distribution = 1.96 
Δ = absolute precision = 0.06 
P= Prevalence of LTBI among diabetic patients in Spain was 42% (31) 
Minimum sample size was 260, and after considering 20% non-response rate, the 
calculated sample size was 312. 
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For objective 2, to calculate the sample size for the associated factors for categorical 
variable, Power and Sample software comparing two proportions for categorical 
variables was used. 
α = 0.05 
Power = 0.8 
P0 = proportion of insulin-dependent in active-TB diabetics was 0.24 (43)  
P1 = proportion of insulin-dependent in LTBI in diabetics was 0.40 
m= ratio between non LTBI to LTBI in diabetics was 1 
Minimum sample size was 264 and after considering 20% non-response rate, the 
calculated sample size was 317. 
 
For objective 2, to calculate the sample size for the associated factors for numerical 
variable, Power and Sample software comparing two means formula was used. The 
calculation of sample size was as follows:  
α=0.05 
Power = 0.8 
σ = 2.8 (standard deviation of mean HbA1c) (44) 
δ = 1.0 (expected detectable difference mean between LTBI and non-LTBI) 
M = 1 
Thus, the sample size calculated was 248. After considering non-respond rate of 20%, 
the number of patients needed in this study was 298.  
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Summary of the sample size calculation for objective 2 was tabulated in Table 4.1 and 
Table 4.2. Since the largest sample size calculated was from objective 2, 317 were taken 
as the sample size for this study.    
 
Table 4.1: Sample size calculation for categorical variables 
 
 
Variables P0 P1 
Minimum 
sample size (n) 
n + 20% non-respond 
rate 
 
Insulin 
dependent(39) 0.24 0.40 264 317 
 
Smoker (33) 0.65 0.45 192 212 
          
 
 
 
 
 
    Table 4.2: Sample size calculation for numerical variables  
 
 
Variables σ δ 
Minimum 
sample size (n) 
n + 20% non-respond 
rate 
 
Age (28) 11.4 5.0 166 199 
 
HbA1c (40) 2.8 1.0 248 298 
          
 
 
 
 
